Evidence map›Paper›PMID 38545084›Full record

ArticleAdvanced functional materials2020

Understanding the in vivo Fate of Advanced Materials by Imaging.

Ran Li, Thomas S C Ng, Michelle A Garlin, Ralph Weissleder, Miles A Miller

Open access · greenAbstract read
In one paragraph

Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. X-Ray Visible Protein Scaffolds by Bulk Iodination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  4. Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ran LiCenter for Systems Biology, Massachusetts General Hospital Research Institute.
Thomas S C NgCenter for Systems Biology, Massachusetts General Hospital Research Institute.
Michelle A GarlinCenter for Systems Biology, Massachusetts General Hospital Research Institute.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital Research Institute.
Miles A MillerCenter for Systems Biology, Massachusetts General Hospital Research Institute.
Massachusetts General Hospital · USHarvard University · US

Funding

Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
Imaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9M
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast CancerR00CA207744 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, MILES A · 2018 to 2020
$747k
NCI NIH HHS R00 CA207744NCI NIH HHS T32 CA079443NCI NIH HHS U01 CA206997
6 · The paper itself

Abstract

Engineered materials are ubiquitous in biomedical applications ranging from systemic drug delivery systems to orthopedic implants, and their actions unfold across multiple time- and length-scales. The efficacy and safety of biologics, nanomaterials, and macroscopic implants are all dictated by the same general principles of pharmacology as apply to small molecule drugs, comprising how the body affects materials (pharmacokinetics, PK) and conversely how materials affect the body (pharmacodynamics, PD). Imaging technologies play an increasingly insightful role in monitoring both of these processes, often simultaneously: translational macroscopic imaging modalities such as MRI and PET/CT offer whole-body quantitation of biodistribution and structural or molecular response, while ex vivo approaches and optical imaging via in vivo (intravital) microscopy reveal behaviors at subcellular resolution. In this review, the authors survey developments in imaging the in situ behavior of systemically and locally administered materials, with a particular focus on using microscopy to understand transport, target engagement, and downstream host responses at a single-cell level. The themes of microenvironmental influence, controlled drug release, on-target molecular action, and immune response, especially as mediated by macrophages and other myeloid cells are examined. Finally, the future directions of how new imaging technologies may propel efficient clinical translation of next-generation therapeutics and medical devices are proposed.

Indexed as

engineered materialsintravital microscopyin vivo Imagingmaterial pharmacologypharmacodynamicspharmacokinetics

Identifiers

PMID38545084
PMCPMC10972611
OpenAlexW3014260763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.